BTAI Quote, Financials, Valuation and Earnings

Omeros has a net margin of -6378.51% compared to BioXcel Therapeutics's net margin of --. BioXcel Therapeutics's return on equity of -- beat Omeros's return on equity of --.

BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 2194.3%. On the other hand Omeros has an analysts' consensus of $36.00 which suggests that it could grow by 470.52%. Given that BioXcel Therapeutics has higher upside potential than Omeros, analysts believe BioXcel Therapeutics is more attractive than Omeros.

BioXcel Therapeutics has a beta of 0.078, which suggesting that the stock is 92.161% less volatile than S&P 500. In comparison Omeros has a beta of 2.421, suggesting its more volatile than the S&P 500 by 142.108%.

BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. Omeros pays out -- of its earnings as a dividend.

BioXcel Therapeutics quarterly revenues are $214K, which are larger than Omeros quarterly revenues of --. BioXcel Therapeutics's net income of -$13.7M is higher than Omeros's net income of -$32.2M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while Omeros's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 1.77x versus -- for Omeros. Usually stocks with elevated PS ratios are considered overvalued.

Organogenesis Holdings has a net margin of -6378.51% compared to BioXcel Therapeutics's net margin of 6.06%. BioXcel Therapeutics's return on equity of -- beat Organogenesis Holdings's return on equity of 0.29%.

BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 2194.3%. On the other hand Organogenesis Holdings has an analysts' consensus of $6.00 which suggests that it could grow by 12.36%. Given that BioXcel Therapeutics has higher upside potential than Organogenesis Holdings, analysts believe BioXcel Therapeutics is more attractive than Organogenesis Holdings.

BioXcel Therapeutics has a beta of 0.078, which suggesting that the stock is 92.161% less volatile than S&P 500. In comparison Organogenesis Holdings has a beta of 1.848, suggesting its more volatile than the S&P 500 by 84.824%.

BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Organogenesis Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. Organogenesis Holdings pays out -- of its earnings as a dividend.

BioXcel Therapeutics quarterly revenues are $214K, which are smaller than Organogenesis Holdings quarterly revenues of $126.7M. BioXcel Therapeutics's net income of -$13.7M is lower than Organogenesis Holdings's net income of $7.7M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while Organogenesis Holdings's PE ratio is 70.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 1.77x versus 1.46x for Organogenesis Holdings. Usually stocks with elevated PS ratios are considered overvalued.

scPharmaceuticals has a net margin of -6378.51% compared to BioXcel Therapeutics's net margin of -155.1%. BioXcel Therapeutics's return on equity of -- beat scPharmaceuticals's return on equity of -370.01%.

BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 2194.3%. On the other hand scPharmaceuticals has an analysts' consensus of $15.17 which suggests that it could grow by 504.25%. Given that BioXcel Therapeutics has higher upside potential than scPharmaceuticals, analysts believe BioXcel Therapeutics is more attractive than scPharmaceuticals.

BioXcel Therapeutics has a beta of 0.078, which suggesting that the stock is 92.161% less volatile than S&P 500. In comparison scPharmaceuticals has a beta of 0.170, suggesting its less volatile than the S&P 500 by 83.044%.

BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. scPharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. scPharmaceuticals pays out -- of its earnings as a dividend.

BioXcel Therapeutics quarterly revenues are $214K, which are smaller than scPharmaceuticals quarterly revenues of $12.2M. BioXcel Therapeutics's net income of -$13.7M is higher than scPharmaceuticals's net income of -$18.8M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while scPharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 1.77x versus 3.07x for scPharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

ZyVersa Therapeutics has a net margin of -6378.51% compared to BioXcel Therapeutics's net margin of --. BioXcel Therapeutics's return on equity of -- beat ZyVersa Therapeutics's return on equity of --.

BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 2194.3%. On the other hand ZyVersa Therapeutics has an analysts' consensus of $70.00 which suggests that it could grow by 3401.4%. Given that ZyVersa Therapeutics has higher upside potential than BioXcel Therapeutics, analysts believe ZyVersa Therapeutics is more attractive than BioXcel Therapeutics.

BioXcel Therapeutics has a beta of 0.078, which suggesting that the stock is 92.161% less volatile than S&P 500. In comparison ZyVersa Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ZyVersa Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. ZyVersa Therapeutics pays out -- of its earnings as a dividend.

BioXcel Therapeutics quarterly revenues are $214K, which are larger than ZyVersa Therapeutics quarterly revenues of --. BioXcel Therapeutics's net income of -$13.7M is lower than ZyVersa Therapeutics's net income of -$2.4M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while ZyVersa Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 1.77x versus -- for ZyVersa Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.